• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFR14A filed by Atara Biotherapeutics Inc.

    5/10/24 4:30:59 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATRA alert in real time by email
    DEFR14A 1 d822757ddefr14a.htm DEFR14A DEFR14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))

     

    ☒

    Definitive Proxy Statement

     

    ☐

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    Atara Biotherapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


    ATARA BIOTHERAPEUTICS, INC.

    2380 Conejo Spectrum Street, Suite 200

    Thousand Oaks, CA 91320

    SUPPLEMENT TO PROXY STATEMENT

    DATED MAY 10, 2024

    FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS

    TO BE HELD ON JUNE 10, 2024

    This supplement (this “Supplement”), dated May 10, 2024, supplements and amends the definitive proxy statement (the “Proxy Statement”) filed by Atara Biotherapeutics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on April 26, 2024 for the Company’s 2024 Annual Meeting of Stockholders to be held on June 10, 2024 (the “Annual Meeting”). This Supplement is being filed to clarify a possible ambiguity with regard to the voting standards and treatment of broker non-votes and to fix a scrivener’s error.

    Accordingly, the Proxy Statement is hereby amended as follows:

    Under the heading “Questions and Answers About These Proxy Materials and Voting—What are broker non-votes and what is broker discretionary voting?”, the last paragraph of the response is amended as follows:

    Other than Proposals 3, 7 and 8, the Company believes that all proposals set forth in this Proxy Statement are considered “non-routine” matters and brokers will not be able to vote on behalf of their clients if no voting instructions have been furnished. A “broker non-vote” share will not affect the determination of whether the matter is approved in Proposals 1, 2, 4, 5 and 6. Please give your broker voting instructions on all proposals to ensure your shares are represented in the vote.

    Under the heading “How many votes are needed to approve each proposal?”, Proposals 4, 5, 6 and 7 in the table are each amended as follows:

     

    Proposal
    Number

      

    Proposal Description

      

    Vote Required for Approval

       Effect of
    Abstentions
       Effect of
    Broker

    Non-Votes

    4

       Approval of our 2024 Equity Incentive Plan    “For” votes from the holders of a majority of shares present in person, present by remote communication, if applicable, or represented by proxy and entitled to vote on the matter    Against    None

    5

       Approval of an automatic annual increase to our 2024 Equity Incentive Plan    "For” votes from the holders of a majority of shares present in person, present by remote communication, if applicable, or represented by proxy and entitled to vote on the matter    Against    None

    6

       Approval of an increase in the shares of common stock available for issuance under our 2014 Employee Stock Purchase Plan    “For” votes from the holders of a majority of shares present in person, present by remote communication, if applicable, or represented by proxy and entitled to vote on the matter    Against    None
    7    Approval of an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock at a ratio ranging from any whole number between 1-for-4 and 1-for-30, as determined by the Board in its discretion, subject to the Board’s authority to abandon such amendments    “For” votes from the holders of a majority of shares present in person, present by remote communication, if applicable, or represented by proxy and entitled to vote on the matter    Against    Not
    applicable;
    brokers
    have
    discretion
    to vote


    Except as specifically supplemented by the information contained herein, this Supplement does not revise or update any of the other information set forth in the Proxy Statement.

    This Supplement does not provide all of the information that is important to your voting decisions at the Annual Meeting, and the Proxy Statement contains other important additional information. This Supplement should be read in conjunction with the Proxy Statement.

    If you have already returned your proxy or voting instruction card or provided voting instructions, you do not need to take any further action unless you wish to change your vote. If you have submitted a proxy and wish to change your vote, you may revoke your proxy and change your vote by following the instructions under the heading “Questions and Answers About These Proxy Materials and Voting – Can I change my vote after submitting my proxy?” of the Proxy Statement.

    Get the next $ATRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRA

    DatePrice TargetRatingAnalyst
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    11/9/2023Outperform → In-line
    Evercore ISI
    11/9/2023Buy → Neutral
    H.C. Wainwright
    11/9/2023$31.00 → $1.00Buy → Neutral
    Mizuho
    7/20/2022$8.00 → $3.00Neutral → Sell
    Citigroup
    7/13/2022$10.00Overweight → Neutral
    JP Morgan
    7/13/2022$16.00 → $5.00Buy → Hold
    Stifel
    5/10/2022$15.00 → $8.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ATRA
    SEC Filings

    View All

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    1/12/26 4:00:16 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

    1/2/26 4:01:26 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Atara Biotherapeutics Inc.

    SCHEDULE 13D/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/25 4:19:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION

    SECAUCUS, N.J., Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Pierre Fabre Pharmaceuticals, Inc. received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) stating that the Agency is unable to approve the tabelecleucel Biologics License Application (BLA) in its present form. We are surprised and deeply disappointed by the FDA's decision, particularly given the urgent and life-threatening unmet medical need faced by patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of standard-of-c

    1/12/26 8:05:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

    Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has completed the transfer of substantially all tab-cel activities, including BLA sponsorship, and associated costs to Pierre Fabre Laboratories Approval of BLA would unlock a $40 Million milestone payment from Pierre Fabre Laboratories Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) for Pos

    11/12/25 9:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd sold $489,019 worth of shares (80,554 units at $6.07) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    1/14/26 9:16:25 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd exercised 48,737 shares at a strike of $0.00 and covered exercise/tax liability with 1 shares (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    12/1/25 5:00:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Nguyen Anhco sold $38,437 worth of shares (2,915 units at $13.19), decreasing direct ownership by 4% to 64,974 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/19/25 4:55:17 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atara Biotherapeutics downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Atara Biotherapeutics from Buy to Hold and set a new price target of $6.00

    1/13/26 10:16:38 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by Evercore ISI

    Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line

    11/9/23 9:00:28 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral

    11/9/23 7:32:43 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Panacea Innovation Ltd bought $670,422 worth of shares (55,000 units at $12.19) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    8/19/25 8:15:04 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Panacea Innovation Ltd bought $186,372 worth of shares (19,335 units at $9.64) (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    7/21/25 9:00:05 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

    4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

    11/15/23 5:07:08 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Financials

    Live finance-specific insights

    View All

    Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

    U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the EBVALLO™ (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one

    1/12/26 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

    11/5/24 4:01:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

    Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

    11/1/23 8:30:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATRA
    Leadership Updates

    Live Leadership Updates

    View All

    CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform

    Experienced, strategic biopharma leader with 40 years of global biopharma experience CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics. "We are delighted to welcome Pascal to our Board of Directors," said Dominik Escher, Ph.D., Chairman of CDR-Life's Board of Directors. "Pascal's remarkable track record in developing and commercializing transformative thera

    5/28/25 8:00:00 AM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

    5/16/25 8:50:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

    Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

    3/23/22 7:30:00 AM ET
    $ATRA
    $NTRA
    $TVTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

    $ATRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 6:10:20 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/14/24 4:17:31 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

    SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

    11/12/24 1:29:52 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care